Skip to main content

Advertisement

SpringerLink
Log in

Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Backgound

Conbercept and ranibizumab have been used to treat retinopathy of prematurity (ROP). However, the clinical effectiveness of conbercept and ranibizumab remains controversial.

Aim

This meta-analysis aimed to compare the effectiveness of conbercept and ranibizumab for treating ROP.

Method

We systematically searched Pubmed, Web of Science, Embase, the Cochrane Library, Ovid, Scopus, China National Knowledge Infrastructure, Wanfang Database, CQVIP, Duxiu Database, SinoMed, and X-MOL to screen relevant studies up to November 2022. Retrospective cohort studies and randomized controlled trials (RCTs) evaluating the effectiveness of conbercept and ranibizumab in treating patients with ROP were selected. The outcomes assessed were the rates of primary cure, ROP recurrence, and retreatment. Statistical analysis was performed using Stata.

Results

Seven studies (n = 989) were selected in the meta-analysis. There were 303 cases (594 eyes) treated with conbercept and 686 patients (1,318 eyes) treated with ranibizumab. Three studies reported the primary cure rate. Compared to ranibizumab, conbercept had a significantly higher primary cure rate (odds ratio [OR] 1.91, 95% confidence interval [CI] 1.05–3.49, P < 0.05). Five studies reported the rate of ROP recurrence, and there were no significant differences between conbercept and ranibizumab (OR 0.62, 95% CI 0.28–1.38, P > 0.05). Three studies reported the rate of retreatment, and the rates were not significantly different between conbercept and ranibizumab (OR 0.78, 95% CI 0.21–2.93, P > 0.05).

Conclusion

Conbercept had a higher rate of primary cure in ROP patients. More RCTs are needed to compare the efficacy of conbercept and ranibizumab in treating ROP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vinekar A, Sinha S, Mohan A, et al. Role of birth order in the development of retinopathy of prematurity in multiple gestation: a study of 1040 Asian Indian premature infants. SN Compr Clin Med. 2022;4(55):5–7.

    Google Scholar 

  2. Du M, Chen T, Yi Su, et al. Research progress on the risk factors of retinopathy of prematurity. Eye Sci. 2020;35(4):249–54.

    Google Scholar 

  3. Justiniano-Becerra YG, Ramirez-Solis F, Aguilar-Morales K, et al. Retinopathy of prematurity: 5 years and 715 patients, an epidemiological analysis. Invest Ophthalmol Vis Sci. 2022;63(7):4201–F0261.

    Google Scholar 

  4. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1(1):CD009734.

    PubMed  Google Scholar 

  5. Jin E, Yin H, Wang Z, et al. Comparison of visual function and fundus structure outcomes in long-term follow-up of retinopathy of prematurity undergoing anti-vascular endothelia growth factor agents and laser treatment. Chin J Ocul Fundus Dis. 2022;38(7):546–50.

    Google Scholar 

  6. Qi X, Chao Z, Xiao J, et al. Anti-VEGF and laser therapy for type 1 retinopathy of prematurity: a Meta analysis. Int Eye Sci. 2021;21(2):285–90.

    Google Scholar 

  7. Kenneth TE, Kertes PJ. Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging. 2006;1(4):451–66.

    Article  PubMed  Google Scholar 

  8. Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2015;22(9):2311–20.

    Google Scholar 

  9. Soll RF. Treatment of retinopathy of prematurity: moving forward with uncertainty. JAMA. 2022;328(4):332–3.

    Article  PubMed  Google Scholar 

  10. Chen X, Lu H, Wang T. Progress of the application of conbercept in ocular neovascular diseases. IES. 2022;22(8):1361–4.

    Google Scholar 

  11. Pediatric Retinology Group of Ophthalmology Professional Committee of Cross-Strait Medical and Health Exchange Association, Fundus Disease Group of Chinese Medical Association Ophthalmology Branch. Expert consensus on intravitreal injection of anti-vascular endothelial growth factor drugs for retinopathy of prematurity. Chin J Ocular Fundus Dis. 2021;37(11):836–40.

  12. Cao R, Li Y, Liu W, et al. Meta-analysis of comparison of IVB and IVR used for retinopathy of prematurity. IES. 2021;21(3):487–92.

    CAS  Google Scholar 

  13. Shi R, Yang L, Qi Y, et al. Comparison of conbercept with ranbizumab for the treatment efficiency of macular edema: a meta-analysis. IES. 2017;17(12):2242–7.

    Google Scholar 

  14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  15. Ai F, Hu K, Shi J, et al. Quality assessment of cohort studies literature on Chinese smoking by using Newcastle-Ottawa-Scale. Chin J Disease Cont Prevent. 2021;25(6):722–9.

    Google Scholar 

  16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  17. Li M, Wang L, Zhang Z, et al. Comparison of the effectiveness of conbercept versus rRanibizumab in the treatment of type 1 retinopathy of prematurity. IES. 2021;21(5):866–71.

    CAS  Google Scholar 

  18. Cheng Y, Zhu X, Linghu D, et al. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol. 2020;98(8):e1004–8.

    Article  CAS  PubMed  Google Scholar 

  19. Jin E, Yin H, Li X, et al. Short-term outcomes after intravitreal injections of conbercept verus ranibizumab for the treatment of retinopathy of prematurity. Retina. 2018;38(8):1595–604.

    Article  CAS  PubMed  Google Scholar 

  20. Zheng B. Anti-vascular endothelial growth factor in the treatment of retinopathy of prematurity. J Fujian Med Univ. 2020:1–18.

  21. Wang Z, Li Q, Yang X, et al. Comparison of the treatment outcomes for retinopathy of prematurity with an intravitreal injection of conbercept or ranibizumab. Chin J Optometry Ophthalmol Visual Sci. 2021;23(11):858–63.

    Google Scholar 

  22. Yang D. Epidemiological study of retinopathy of prematurity in dalian and short term efficacy of Anti-VEGF therapy. J Dalian Med Univ. 2019:1–34.

  23. Wu Z, Zhao J, Lam W, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022;106(7):975–9.

    Article  PubMed  Google Scholar 

  24. Liu W, Li Y, Cao R, et al. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion. Medicine (Baltimore). 2020;99(21): e20222.

    Article  PubMed  Google Scholar 

  25. Bai F, Ma X, Yan Y, et al. Comparison of the efficacy of ranibizumab and conbercept in the treatment of age-related macular degeneration. Chin J Gerontol. 2020;40(04):826–8.

    CAS  Google Scholar 

  26. Liu J, Gong J. Effects of ranibizumab and compaqip on BCVA, PLT and CMT in branch vein occlusion combined with macular edema. J Guangxi Univ(Natural Science). 2020;45(2):458–63.

    Google Scholar 

  27. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1):204–10.

    Article  CAS  PubMed  Google Scholar 

  28. Stephens RJ, Dettmer MR, Roberts BW, et al. Practice patterns and outcomes associated with early sedation depth in mechanically ventilated patients: a systematic review and meta-analysis. Crit Care Med. 2018;46(3):471–9.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7): e1002595.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Suárez-Iglesias D, Miller KJ, Seijo-Martínez M, et al. Benefits of Pilates in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Medicina. 2019;55(8):47.

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Author notes

  1. The authors Wei Huang and Pan Hu have contributed equally to this work.

  2. The authors Shichun Jiang and Xin Li are Co-first authors.

Authors and Affiliations

  1. Department of Ophthalmology, Daping Hospital, Army Medical University, Chongqing, China

    Shichun Jiang, Xin Li, Min Fu, Donghan Huanglu, Ju Huang, Wei Huang & Pan Hu

Authors
  1. Shichun Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donghan Huanglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ju Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Huang.

Ethics declarations

Conflicts of Interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 15 KB)

Supplementary file2 (DOCX 15 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, S., Li, X., Fu, M. et al. Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis. Int J Clin Pharm 45, 1317–1325 (2023). https://doi.org/10.1007/s11096-023-01584-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-023-01584-y

Keywords

Search

Navigation